Funded Biotechnology Startups in Sydney
The biotech funding set centered on Sydney is dominated by one disclosed round: AdvanCell’s $315M (Series D) on 2026-07-15 dwarfs the next-largest disclose…
The biotech funding set centered on Sydney is dominated by one disclosed round: AdvanCell’s $315M (Series D) on 2026-07-15 dwarfs the next-largest disclosed amount at $60M (Immutep, 2024-06-05), with the remaining disclosed rounds generally concentrated below $20M (e.g., Proto Axiom $20M on 2024-08-12; Imugene $9M on 2026-04-23). Temporal clustering is also visible: nine of the 11 entries fall between 2023-09-22 and 2026-07-15, and three biotech rounds (Imugene $9M on 2026-04-23, Algenie $990K on 2026-05-21, AdvanCell $315M on 2026-07-15) were disclosed within about three months in 2026.
All 11 companies list Sydney, New South Wales as their city (no geographic variance within the page). On stage mix, five of 11 entries are “Series Unknown” (Algenie, Imugene, SWAN Genomics, Psylo, Beroni Group), while the largest known stage label is the $315M Series D at AdvanCell; disclosed amounts span 2021-05-10 (SpeeDx $2M) to 2026-07-15 (AdvanCell $315M).
Most recent rounds
11 shownRelated listings
Frequently asked
What’s the largest disclosed round for biotech startups in Sydney, and how sharply does it stand out versus the rest?
AdvanCell’s $315M (Series D) on 2026-07-15 is the clear outlier: the next-largest disclosed amount is Immutep’s $60M (2024-06-05), and the remaining disclosed rounds fall below $20M (including Proto Axiom at $20M on 2024-08-12 and Imugene at $9M on 2026-04-23).
Are there any tight time windows where multiple rounds close in quick succession?
Yes. In 2026, three disclosed rounds appear within roughly three months: Imugene ($9M) on 2026-04-23, Algenie ($990K) on 2026-05-21, and AdvanCell ($315M) on 2026-07-15. More broadly, the dataset skews recent, with 9 of 11 entries dated 2023-09-22 through 2026-07-15.
Does the list over-represent any city or geography?
No variation within the page: all 11 entries list Sydney, New South Wales, Australia. That makes Sydney the only repeated geography in the shown cohort.
What stage labeling dominates this biotech set, and what are the main known-stage anchors?
“Series Unknown” appears in 5 of 11 entries (Algenie, Imugene, SWAN Genomics, Psylo, Beroni Group). Among known labels, the major anchor is AdvanCell’s Series D at $315M (2026-07-15), with Proto Axiom’s Series B at $20M (2024-08-12) as the next-largest named stage amount.
Are there any notably small disclosed rounds worth flagging against the rest of the distribution?
Beroni Group is the smallest disclosed amount at $210K (2023-09-22). SpeeDx is also low relative to the mid-to-high disclosed rounds at $2M (2021-05-10), while most other disclosed amounts sit between $3M and $20M (e.g., Psylo $3M on 2024-10-29; BCAL Diagnostics $11M on 2024-06-03).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.